Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Celtics Live

84

100

Final

Bruins Live

2

2

2nd Prd 3:17

Patriots Live

17

16

Final

Amylin, Alkermes get OK for diabetes drug

WASHINGTON - Amylin Pharmaceuticals won approval yesterday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company’s 7-year old diabetes medicine, Byetta.

Bydureon is a once-a-week version of Byetta, which is taken twice a day to control blood sugar. Amylin executives say the drug’s convenient regimen will give it a competitive advantage. However, after multiple delays it enters a crowded market, including one diabetes treatment in the same class that has shown superior results.

Continue reading below

The Food and Drug Administration approval comes after two rejections in 2010, when the agency asked Amylin to conduct a new study of the drug’s effects on the heart.

Bydureon was codeveloped with Eli Lilly, which also helped comarket Byetta. Both drugs are scheduled to transfer to Amylin by the end of 2013. Alkermes, based in Waltham, Mass., created Bydureon’s formulation technology, which gradually releases the drug over the course of a week.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com